RSRashmi Sarkar

Rashmi Sarkar

*This is an algorithmically generated author record based on publicly available information.

Rashmi Sarkar has a total of 257 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cosmeceuticals for hyperpigmentation: An evidence-based review

    by Rashmi Sarkar, Anika Saini

    Hyperpigmentation disorders such as melasma and post-inflammatory hyperpigmentation are common concerns in dermatology particularly in darker skin types. This narrative review evaluates the efficacy, mechanisms, and safety of cosmeceuticals used in their management, with relevance to Indian practice. A literature search (2013–2026) identified clinical and experimental studies on topical and systemic agents. Traditional depigmenting agents including hydroquinone, azelaic acid, and kojic acid act primarily through tyrosinase inhibition but are limited by tolerability concerns. Newer cosmeceuticals such as thiamidol, cysteamine, tranexamic acid and resorcinol derivatives provide targeted, multi-pathway effects with improved safety profiles. Adjunctive agents including Vitamin C, niacinamide, and various botanicals offer antioxidant, anti-inflammatory and barrier-restoring benefits. Although these agents show promising results, further large-scale studies with standardized outcomes are needed to establish long-term efficacy and optimize treatment strategies.

  • Rethinking Corticosteroids in the Kligman–Willis Formula for Melasma

    by Marina Landau, Jane M. Grant‐Kels, Fotini Bageorgou, Rashmi Sarkar, Mohamad Goldust

    Melasma necessitates effective long‐term management that goes beyond initial treatment. Although the Kligman–Willis triple combination is the standard induction therapy, prolonged use of corticosteroids raises safety concerns. We propose a maintenance strategy that spares corticosteroids while still utilizing a formulation that has been proven over the years to be the most effective for treating melasma. This approach aims to enhance safety by omitting corticosteroids.

  • Open Access

    The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data

    by Luigi Naldi, Simone Cazzaniga, Carsten Flohr, Marco May Lee, Claire Fuller, Roderick Hay, Esther E. Freeman, Rashmi Sarkar, Ricardo Romiti, Antonio Torrelo, et al.

    Background: Skin diseases represent a major public health concern, affecting all demographics and imposing significant personal, economic and social burdens. Objectives: To assess the epidemiology and impact of skin diseases using the Global Burden of Disease (GBD) data, highlighting regional variations, knowledge gaps and areas for improvement. Methods: GBD data on prevalence, incidence, disability‐adjusted life years (DALYs) and years lived with disability (YLDs) for skin conditions from 2000 to 2021 were analysed. Results: According to GBD 2021, the global prevalence of skin and subcutaneous diseases, excluding sexually transmitted infections (STIs) and skin cancers, was 25.7%, ranking sixth among the most prevalent disease categories worldwide. These conditions accounted for a global YLDs rate of 495.1 per 100,000 person‐years, placing them eighth in terms of disease burden. Overall, the most prevalent conditions were STIs excluding HIV (16.8%), fungal infections (7.8%), and acne (3.0%). Squamous cell carcinoma, basal cell carcinoma and decubitus ulcers showed increasing prevalence, while atopic dermatitis, scabies and viral infections declined slightly. Acne, scabies and atopic dermatitis predominated in youth, whereas fungal infections, contact dermatitis and skin cancers predominated in older adults. Females showed higher prevalence of STIs, acne and atopic dermatitis. Infectious skin diseases were more common in Sub‐Saharan Africa and tropical regions, while chronic inflammatory and neoplastic diseases predominated in high‐income regions. Conclusions: Several limitations were identified. The GBD initiative only includes some dermatological diseases reflecting the difficulties in obtaining data because of the multitude of skin diseases with underreporting and misdiagnosis. There are significant gaps in data from low‐ and middle‐income countries, a lack of reliable trends and inadequate quality‐adjusted life year estimates considering cultural and social variations. The GBD initiative provides valuable insights but underestimates the true burden of skin diseases. Improved reporting and inclusion of neglected conditions are urgently needed through global collaboration among stakeholders.


  • Open Access

    Expert Consensus on the Management of Hyperpigmentation Disorders in India: A Modified Delphi Study by the Pigmentary Disorders Society

    by Rashmi Sarkar, Sunil Dogra, Surabhi Sinha, Keshavamurthy Vinay, Indrashis Podder, Anupam Das, Bhavesh Swarnkar, B. S. Chandrashekar, Hitaishi Mehta, Madhuri Agarwal, et al.

    Hyperpigmentation disorders are prevalent in individuals with skin of color and are associated with considerable psychosocial impact. Clinical heterogeneity, chronic relapsing course, and limited evidence often result in suboptimal outcomes. This consensus aimed to develop evidence‐informed, expert consensus recommendations for the diagnosis and management of common hyperpigmentation disorders in the Indian context. A modified Delphi study was conducted by Indian experts of the Pigmentary Disorders Society (PDS) between August 2025 and January 2026. Twelve dermatologists with expertize in pigmentary disorders participated. An exploratory round identified four priority conditions: melasma, acquired dermal macular hyperpigmentation, post‐inflammatory hyperpigmentation, and periorbital hyperpigmentation. A broad literature review informed the development of the statements. Two rounds of anonymous voting using a 5‐point Likert scale and a virtual meeting were undertaken. Consensus was predefined as high (≥ 75%), moderate (55%–74%), or low (< 55%). In Round 1, 34 statements were evaluated; 21 achieved high consensus, 9 moderate, and 4 low. Following the virtual discussion and refinement, 11 revised statements were revoted on in Round 2, resulting in 32 final high‐consensus statements. Key recommendations emphasized proactive prevention and relapse minimization in Fitzpatrick skin types III–VI, the use of dermoscopy and Wood's lamp for aiding diagnosis, and the use of histopathology when indicated. Overall, the consensus favored combination approaches targeting melanogenesis, inflammation, and photoprotection. The panel also outlined preferred topical, oral, and procedural options based on existing evidence and clinical experience. Overall, this consensus provides contextualized guidance for major hyperpigmentation disorders, emphasizing individualized and multimodal management. image

  • When Does Pigment Matter? Toward a Context‐Aware Standard for Representation in Dermatology

    by Hitaishi Mehta, Sejal Jain, Rashmi Sarkar

    Current calls to improve representation in dermatology often invoke “skin of color,” diversity, or inclusion, but rarely specify when skin‐tone variation is clinically essential versus when proportional documentation is sufficient. This ambiguity risks reducing representation to a generalized diversity metric rather than a clinically meaningful reporting standard. We propose a context‐aware, three‐tier triage model for dermatology research and educational resources based on skin tone or pigment phenotype. Pigment‐critical domains are those in which skin tone directly alters diagnostic visibility, morphologic cues, dyspigmentation or scarring risk, or procedural safety, and therefore require intentional tonal breadth. Pigment‐modulated domains are those in which skin tone influences sequelae, treatment response, or patient‐reported outcomes, whereas the core phenotype remains recognizable across tones; these warrant proportional inclusion and tone‐stratified reporting when clinically meaningful. Pigment‐neutral domains are those in which skin tone has minimal relevance to the specific clinical question or endpoint; these may mirror local epidemiology while still reporting tone distribution for transparency. Aligning representation with pigment relevance offers a practical minimum standard for authors, reviewers, and journals.

  • Open Access

    An Unusual Case of Mycetoma Caused by Fusarium solani

    by Rashmi Sarkar, Taku Rini, Apaopa Jemima Thekho, Deepti Rawat

  • Open Access

    Facial Melanosis: A Comprehensive Review of Uncommon and Common Presentations with Personal Experience

    by Rashmi Sarkar, Damini Verma

    Facial melanoses (FMs) encompass a diverse group of disorders characterised by altered facial pigmentation, particularly prevalent in individuals with darker skin types, such as the Indian population. While common causes like melasma, post-inflammatory hyperpigmentation, and lichen planus pigmentosus are well documented in the literature, this review emphasises the lesser-known and uncommon causes of FM. These include facial acanthosis nigricans, maturational hyperpigmentation, frictional facial melanosis, and seborrheic melanosis, which are frequently observed in Indian populations but remain underrecognised and understudied. The aetiology of FM is multifactorial, involving genetic predisposition, racial factors, ultraviolet radiation, and exposure to photosensitising chemicals and allergens. Uncommon causes often present unique diagnostic challenges and are frequently misdiagnosed due to their overlapping clinical features. Diagnosis relies on clinical evaluation, supported by Wood’s lamp examination, dermoscopy, and, in some cases, skin biopsy. FM can be classified into brown, blue, or mixed hypermelanosis based on the location and nature of melanin deposition. Management of these uncommon conditions is complex and requires a nuanced approach. Photoprotection remains a cornerstone of therapy, alongside topical depigmenting agents, chemical peels, and laser or light-based interventions. However, the risk of post-inflammatory hyperpigmentation in richly pigmented skin necessitates cautious and individualised treatment strategies. The lack of standardised guidelines for these uncommon causes further complicates management, underscoring the need for tailored therapeutic approaches. This review highlights the clinical significance of recognising and addressing uncommon causes of FM, which significantly impact patients’ quality of life and psychosocial well-being. Enhanced awareness, further research, and the development of evidence-based treatment protocols are essential to improve outcomes for patients with these understudied conditions. By focussing on these uncommon causes, this review aims to fill a critical gap in the literature and provide a comprehensive resource for clinicians managing facial melanoses in skin of colour. Such comprehensive articles are lacking in literature.

  • Open Access

    Global consensus on the management of melanin hyperpigmentation disorders

    by Thierry Passeron, Seemal R. Desai, Marwa Abdallah, Firas Al‐Niaimi, Ncoza Dlova, Pearl E. Grimes, Jorge Ocampo‐Candiani, Rashmi Sarkar, Leihong Flora Xiang, Helio Amante Miot

    Melanin hyperpigmentation disorders (MHD) are among the most prevalent dermatologic concerns globally, affecting individuals across all skin phototypes and geographies. Despite their widespread impact on quality of life—including stigmatization, anxiety and depression—comprehensive, unified and practical clinical guidelines are lacking. This global consensus project convened 10 leading dermatologists and pigmentary disorder experts from Africa, Asia, Europe and the Americas to develop an evidence‐based, internationally applicable framework for the management of common MHD, including melasma, post‐inflammatory hyperpigmentation, acquired dermal macular hyperpigmentation, periorbital hyperpigmentation, chronic hyperpigmentary photodamage, freckles/ephelides and hyperpigmentation of the folds. Based on a comprehensive literature review and a structured Delphi process, the expert panel formulated consensus statements and tailored treatment algorithms that account for skin type, photobiological behaviour, disease severity and regional access to therapies. Special emphasis was placed on the role of broad‐spectrum photoprotection and the challenges of tinted sunscreen availability in diverse populations. Treatment options ranged from topical lightening agents and systemic therapies (e.g. oral tranexamic acid) to procedural interventions (e.g. chemical peels, lasers and IPL) stratified by disease subtype and pigmentation depth. Notably, the consensus highlights that effective MHD management must address not only melanocytes but also the surrounding skin microenvironment, including fibroblasts, mast cells and vascular components. This consensus provides a globally adaptable clinical guide for the diagnosis and management of MHD, emphasizing a personalized approach that bridges scientific rigour with real‐world applicability across diverse populations and health systems.


  • Open Access

    Infectious complications in esthetic dermatology procedures: A narrative review

    by Rashmi Sarkar, Apaopa Jemima Thekho, Taku Rini

    Minimally invasive esthetic procedures for rejuvenation are increasing exponentially worldwide. They include a range of products, both pharmaceutical and non-pharmaceutical. Most of the procedures are well tolerated with a high safety profile and minimal adverse events. However, infectious complications following esthetic procedures, though relatively rare, can lead to significant morbidity and impact the outcome of esthetic treatments. They typically result from the introduction of pathogenic bacteria during the procedure, either from contaminated equipment, improper aseptic technique, or after the procedure if proper wound care is not followed. It occurs due to a combination of various factors, including lack of regulation and licensing, lack of structured, quality-assured training, and performance of these procedures by non-dermatologists or untrained personnel. Approaches to prevent and manage infectious complications by timely diagnosis and appropriate management are of the utmost importance. In this paper, we discuss the various infectious complications and provide advice on how to minimize adverse events and complications from these injectables.


  • Open Access

    Standardising the diagnosis and management of atopic dermatitis in India: A consensus statement by the modified Delphi method by IADVL Special Interest Group of Pediatric Dermatology (STAND AD)

    by Rashmi Sarkar, Liza Mohapatra, Divya Gupta, Seetharam Anjaneyulu Kolalapudi, Rahul Mahajan, Prabhakaran Nagendran, Maitreyee Panda, Krina Bharat Patel, ShitalAmin Poojary, Prabhakar Mallikarjuna Sangolli, et al.

    Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder with a significant impact on psychosocial health and quality of life. Despite growing prevalence in India, particularly among adults, a comprehensive, India-specific guideline incorporating recent advances is lacking. Objective: To develop a standardised, evidence-based consensus on the diagnosis and management of paediatric and adult AD in India through a modified Delphi methodology. Methods: A total of 14 dermatology experts across India, with over 15 years of clinical and academic experience, formed the Special Interest Group of Paediatric Dermatology under IADVL. A systematic literature review was conducted using databases such as PubMed, Embase, and Cochrane, focusing on Indian and global literature up to December 2024. Based on this, 29 draft statements were generated covering domains of diagnosis, severity assessment, non-pharmacological measures, and topical and systemic therapies. A two-round, web-based, modified Delphi process was conducted anonymously to reach consensus. Statements with ≥75% agreement were retained. Results: Consensus was achieved on all 29 statements. Thirteen statements were finalised after the first round, and 16 were refined and approved in the second round. Key recommendations included the use of modified Hanifin and Rajka criteria for diagnosis, SCORAD and IGA for severity assessment, therapeutic patient education, and individualised use of moisturisers, topical corticosteroids, and topical calcineurin inhibitors. For systemic therapy, cyclosporine remains first-line for moderate-to-severe AD, with conditional recommendations for methotrexate, mycophenolate, and JAK inhibitors such as abrocitinib. Emerging therapies like topical tofacitinib and crisaborole were discussed with caution due to limited Indian data. Limitations: Although several new therapies, such as abrocitinib and dupilumab, have been approved for pediatric atopic dermatitis, consensus among Delphi panelists remains limited. There is lack of sufficient clinical experience and pediatric-specific data on these agents, highlighting the urgent need for more robust studies to inform expert alignment and clinical practice. Conclusion: This updated Indian consensus guideline provides comprehensive, evidence-based, and context-sensitive recommendations for diagnosing and managing AD across age groups. It addresses previously unmet needs in adult AD. This consensus is expected to enhance clinical outcomes and standardise AD management nationally.